[See Warnings and Precautions (5.1)] A composite safety endpoint intended to capture clinically significant neuropsychiatric (NPS) adverse events included the following NPS adverse events: anxiety, depression, feeling abnormal, hostility, agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, irritability, suicidal ideation, suicidal behavior or completed suicide
Often blended with Dark Virginias, for a smoke you know you have had
Philip Morris research underscores the fact that fewer toxic chemicals does not mean lower levels of harm when people use the product, and that reduced exposure claims are misunderstood as reduced harm claims
For more information, fill out a free case evaluation form today
The study authors acknowledge a shortcoming of the study: more than half of the patients in each treatment group stopped therapy before the 12-week regimen was completed